Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Wheeler; Larry A.
Address:
Irvine, CA
No. of patents:
62
Patents:


1 2










Patent Number Title Of Patent Date Issued
8580292 Sustained release intraocular implants and methods for treating ocular vasculopathies November 12, 2013
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic
8293741 Intraocular implants and methods for improving vision October 23, 2012
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic
8293210 Sustained release intraocular implants and methods for preventing retinal dysfunction October 23, 2012
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic
8178571 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or sel May 15, 2012
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are used to activate alpha.sub.2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including
8153645 Treating pain using selective antagonists of persistent sodium current April 10, 2012
The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
8124612 Treating neurological disorders using selective antagonists of persistent sodium current February 28, 2012
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium
8071635 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazo December 6, 2011
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only mi
8063087 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazo November 22, 2011
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only mi
8063086 Imidazole-2-thiones November 22, 2011
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only minimal
7960423 Imidazole-2-thiones June 14, 2011
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only mi
7893107 Therapeutic methods using prostaglandin EP.sub.4 agonist components February 22, 2011
Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP.sub.4 agonist component to a mammal afflicted with or prone to afflicted with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, non-s
7838545 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists November 23, 2010
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in prefere
7829587 Substituted 2-aminotetralin derivatives as selective alpha 2B agonist November 9, 2010
Substituted 2-aminotetralin derivatives as selective alpha 2B agonists can be incorporated in a pharmaceutical composition and can be used in methods of treating an alpha 2B receptor mediated diseases or conditions. The compounds are represented by Formula 1: ##STR00001## wherein
7795292 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or sel September 14, 2010
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are used to activate alpha.sub.2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including human
7767718 Treating pain using selective antagonists of persistent sodium current August 3, 2010
The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
7763651 Treating pain using selective antagonists of persistent sodium current July 27, 2010
The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
7754768 Methods and compositions for modulating alpha adrenergic receptor activity July 13, 2010
Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.
7728034 Treating neurological disorders using selective antagonists of persistent sodium current June 1, 2010
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium
7705055 Treating neurological disorders using selective antagonists of persistent sodium current April 27, 2010
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium
7683089 4-(Phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adre March 23, 2010
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in prefere
7612082 Prostaglandin EP.sub.4 antagonists November 3, 2009
Disclosed herein are methods and compositions related to compound 1 or compound 2 ##STR00001## or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP.sub.4 receptor, or are prostaglandin EP.sub.4 antagonists.
7569595 2-((2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronaphthalen-1(- 2H)-one August 4, 2009
A compound of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, is disclosed herein. Methods and compositions related thereto are also disclosed.
7419994 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazo September 2, 2008
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only minimal
7399868 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adr July 15, 2008
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference
7396849 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as .alpha..sub.2 adrenergic agonists July 8, 2008
Compounds of Formula 1 ##STR00001## where the variables have the meaning defined in the specification are agonists of alpha.sub.2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in prefere
7358269 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2- H)-one April 15, 2008
A compound of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, is disclosed herein. Methods and compositions related thereto are also disclosed.
7345077 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazo March 18, 2008
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only minimal
7335803 Methods and compositions for modulating alpha adrenergic receptor activity February 26, 2008
Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use.
7323485 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazo January 29, 2008
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only minimal
7125908 Treating pain using selective antagonists of persistent sodium current October 24, 2006
The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.
7091232 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazo August 15, 2006
Compounds of Formula 1 ##STR00001## where X is S and the variables have the meaning defined in the specification are specific or selective to alpha.sub.2B and/or alpha.sub.2C adrenergic receptors in preference over alpha.sub.2A adrenergic receptors, and as such have no or only minimal
7060723 Treating neurological disorders using selective antagonists of persistent sodium current June 13, 2006
The present invention provides methods of treating neurological disorders in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium
6841684 Imidiazoles having reduced side effects January 11, 2005
Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.
6573271 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agoni June 3, 2003
Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a
6465464 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury October 15, 2002
The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or de
6372753 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agoni April 16, 2002
Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a
6329369 Methods of treating pain and other conditions December 11, 2001
Methods of treating glaucoma or elevated pressure and other diseases with reduced side effects by treating a mammal in need thereof an agonist of the alpha 2B or alpha 2B/2C adrenergic receptor(s). Also described are compounds having such selective agonist activity.
6323204 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives November 27, 2001
A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1##and pharmaceutically acceptable acid addition salts thereof an
6313172 Methods and compositions for modulating alpha adrenergic receptor activity November 6, 2001
Methods and compositions for the treatment of pain using this area derivatives. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.
6248741 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury June 19, 2001
The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or de
6194415 Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury February 27, 2001
The present invention provides a method of protecting the optic or retinal nerve cells of a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on said nerve cells an effective amount of a compound of formula I to inhibit or prevent nerv
6075032 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agoni June 13, 2000
Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a
6071924 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agoni June 6, 2000
Proliferation of retinal pigment epithelium following surgery or trauma is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR) agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR
5863892 Use of platelet derived growth factor in ophthalmic wound healing January 26, 1999
A method of accelerating corneal wound healing in the corneal anterior stroma and/or improving the quality of wound healing in a mammal comprises: (1) providing an ophthalmically compatible solution of platelet-derived growth factor; and (2) applying the solution to the cornea of a m
5856329 Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury January 5, 1999
A method according to which neuroprotection is conferred upon ocular nerve cells by administration of a drug of formula I to the optic nerve and/or retina of a mammal within a period prior to or following an insult to ocular nerve cells but prior to cell death ##STR1## wherein th
5824685 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agoni October 20, 1998
Proliferation of retinal pigment epithelium following surgery or trauma is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR) agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR
5773440 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives June 30, 1998
A method of treating a mammal is disclosed comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## , and pharmaceutically acceptable acid a
5756503 Methods for using (2-imidazolin-2-ylamino) Quinoxaline derivatives May 26, 1998
A method of treating a mammal is disclosed comprising administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid ad
5721215 Injectable therapy for control of muscle spasms and pain related to muscle spasms February 24, 1998
A method for administration of botulinum toxin, includes the steps of (a) selecting at least one neuromuscular blocking agent having a duration of activity shorter than neuromuscular blocking activity of botulinum toxin; (b) selecting at least one muscle of a muscle group; (c) intramuscu
5714486 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives February 3, 1998
A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts there
1 2










 
 
  Recently Added Patents
Perception-based artifact quantification for volume rendering
Computerized apparatus for identifying industries for potential transfer of a job function
Tool box
Vaccine composition against Streptococcus pyogenes
Method and apparatus for compensating QoS during handover by base station in wireless broadband access system
Flash drive
Housing for gas flow indicator
  Randomly Featured Patents
Process for the preparation of an alkyl vinyl ether/maleic anhydride copolymer
Shower head
Method of measuring thymopoietin proteins in plasma and serum including acidification of the plasma and serum
Synthesis of substituted dioxolanes by direct oxidation of olefins over molybdenum 8-hydroxyquinoline
Waterslide bowl structure and method of construction
Two rotor sliding vane compressor
Rotation-stabilizing ambient gaseous fluid guide for rotary and storage devices
Fluorescent lamp substantially approximating the ultraviolet spectrum of natural sunlight
Buffer circuit with voltage clamping and method
Front face of a vehicle wheel